Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.12 USD | +7.75% | +22.84% | -38.94% |
05-14 | Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing | MT |
05-09 | Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.94% | 467M | |
+27.66% | 49.18B | |
+0.94% | 42.11B | |
+50.41% | 40.37B | |
-5.26% | 28.85B | |
+13.23% | 26.09B | |
-21.79% | 18.71B | |
+10.19% | 13.26B | |
+31.87% | 12.32B | |
+0.03% | 11.99B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- JPMorgan Upgrades Editas Medicine to Neutral From Underweight, Price Target is $8